In the BioHarmony Drug Report Database

"Preview" Icon

Nusinersen

Spinraza (nusinersen) is an oligonucleotide pharmaceutical. Nusinersen was first approved as Spinraza on 2016-12-23. It is used to treat spinal muscular atrophy in the USA. It has been approved in Europe to treat spinal muscular atrophy. Spinraza’s patents are valid until 2035-09-11 (FDA).

 

Trade Name

 

Spinraza
 

Common Name

 

nusinersen
 

ChEMBL ID

 

CHEMBL3301572
 

Indication

 

spinal muscular atrophy
 

Drug Class

 

Antisense oligonucleotides

Image (chem structure or protein)

Nusinersen structure rendering